These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

504 related items for PubMed ID: 26058570

  • 1. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
    Dhanasekaran R, Sanchez W, Mounajjed T, Wiesner RH, Watt KD, Charlton MR.
    Liver Int; 2015 Nov; 35(11):2433-41. PubMed ID: 26058570
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
    Lim KB, Sima HR, Fiel MI, Khaitova V, Doucette JT, Chernyiak M, Ahmad J, Bach N, Chang C, Grewal P, Kim-Schluger L, Liu L, Odin J, Perumalswami P, Florman SS, Schiano TD.
    World J Gastroenterol; 2015 May 28; 21(20):6236-45. PubMed ID: 26034358
    [Abstract] [Full Text] [Related]

  • 4. Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C.
    Pillai AA, Lee VS, Wang E, Rinella ME, Levitsky J.
    Transplant Proc; 2010 Nov 28; 42(9):3647-51. PubMed ID: 21094833
    [Abstract] [Full Text] [Related]

  • 5. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
    Iacob S, Gheorghe L, Hrehoret D, Becheanu G, Herlea V, Popescu I.
    J Gastrointestin Liver Dis; 2008 Jun 28; 17(2):165-72. PubMed ID: 18568137
    [Abstract] [Full Text] [Related]

  • 6. Recurrent hepatitis C virus infection and outcome after living-donor liver transplant.
    Satapathy SK, Fiel MI, Vanatta JM, Del Rio Martin J, Schiano TD.
    Exp Clin Transplant; 2013 Dec 28; 11(6):522-9. PubMed ID: 23901801
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation.
    Ackefors M, Castedal M, Dahlgard O, Verbaan H, Gjertsen H, Wernerson A, Weiland O.
    Infect Dis (Lond); 2015 Apr 28; 47(4):209-17. PubMed ID: 25650729
    [Abstract] [Full Text] [Related]

  • 10. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN.
    Liver Transpl; 2008 Jan 28; 14(1):53-8. PubMed ID: 18161839
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, Crawford JM, Davis GL, Nelson DR.
    Liver Transpl; 2004 Feb 28; 10(2):199-207. PubMed ID: 14762857
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V, Stampori M, Lisgos P, Pselas C, Prodromidou K, Karatapanis S.
    Eur J Gastroenterol Hepatol; 2013 Jul 28; 25(7):798-805. PubMed ID: 23395996
    [Abstract] [Full Text] [Related]

  • 15. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
    Giordanino C, Sacco M, Ceretto S, Smedile A, Ciancio A, Cariti G, De Blasi T, Picciotto A, Marenco S, Grasso A, Pirisi M, Smirne C, Colletta C, Traverso A, Mazzucco D, Ciccone G, Simondi D, Rizzetto M, Saracco G.
    Eur J Gastroenterol Hepatol; 2014 Jan 28; 26(1):52-8. PubMed ID: 23719564
    [Abstract] [Full Text] [Related]

  • 16. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
    Ogawa E, Furusyo N, Shimizu M, Ihara T, Hayashi T, Harada Y, Toyoda K, Murata M, Hayashi J.
    Antivir Ther; 2015 Jan 28; 20(2):185-92. PubMed ID: 24941012
    [Abstract] [Full Text] [Related]

  • 17. Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin.
    Giusto M, Rodriguez M, Navarro L, Rubin A, Aguilera V, San-Juan F, Ortiz C, López-Andujar R, Prieto M, Berenguer M.
    Liver Transpl; 2011 Nov 28; 17(11):1318-27. PubMed ID: 21761553
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.
    Gheorghe L, Iacob S, Grigorescu M, Sporea I, Sirli R, Damian D, Gheorghe C, Iacob R.
    J Gastrointestin Liver Dis; 2009 Mar 28; 18(1):51-6. PubMed ID: 19337634
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.